Long-Term Persistence and Monotherapy with Device-Aided Therapies: A Retrospective Analysis of an Israeli Cohort of Patients with Advanced Parkinson's Disease.

Avner ThalerYael BarerRuth GrossRaanan CohenLars BergmannYash J JalundhwalaNir GiladiGabriel ChodickVarda ShalevTanya Gurevich

Published in: Advances in therapy (2022)

DAT are well maintained in patients with advanced PD. These retrospective data suggest that patients receiving LCIG may have higher long-term persistence rates compared with patients receiving CSAI. A subgroup of patients was treated with DAT as monotherapy without additional oral anti-parkinsonian therapy, with LCIG showing the highest rates.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
combination therapy
open label
prognostic factors
peritoneal dialysis
stem cells
clinical trial
randomized controlled trial
big data
machine learning
patient reported outcomes
data analysis